C4 Therapeutics Inc
NASDAQ:CCCC

Watchlist Manager
C4 Therapeutics Inc Logo
C4 Therapeutics Inc
NASDAQ:CCCC
Watchlist
Price: 4.95 USD -3.51% Market Closed
Market Cap: 343.2m USD
Have any thoughts about
C4 Therapeutics Inc?
Write Note

EV/FCFF
Enterprise Value to FCFF

-1.3
Current
-1.2
Median
3.8
Industry
Lower than median
Lower than industry value

Enterprise Value to Free Cash Flow To Firm (EV/FCFF) ratio is a valuation multiple that compares the value of a company, debt included, to the amount of free cash flow available for all stakeholders. This metric is very similar to the EV/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.

EV/FCFF
-1.3
=
Enterprise Value
93.6m USD
/
FCFF
-71.6m USD
All Countries
Close
Market Cap EV/FCFF
US
C4 Therapeutics Inc
NASDAQ:CCCC
349.3m USD -1.3
FR
Pharnext SCA
OTC:PNEXF
6T USD -235 459.5
US
Abbvie Inc
NYSE:ABBV
300.2B USD 22.5
US
Amgen Inc
NASDAQ:AMGN
158.7B USD 32.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
126.8B USD -84.4
US
Gilead Sciences Inc
NASDAQ:GILD
115B USD 11
US
Epizyme Inc
F:EPE
94.1B EUR -476.4
AU
CSL Ltd
ASX:CSL
137.3B AUD 65.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
88.3B USD 24.5
US
Seagen Inc
F:SGT
39.3B EUR -57.5
NL
argenx SE
XBRU:ARGX
34.1B EUR -101.2
 
US
C4 Therapeutics Inc
NASDAQ:CCCC
Average EV/FCFF: 31.3
Negative Multiple: -1.3
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -235 459.5
US
Abbvie Inc
NYSE:ABBV
22.5
US
Amgen Inc
NASDAQ:AMGN
32.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -84.4
US
Gilead Sciences Inc
NASDAQ:GILD
11
US
E
Epizyme Inc
F:EPE
Negative Multiple: -476.4
AU
CSL Ltd
ASX:CSL
65.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
24.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -57.5
NL
argenx SE
XBRU:ARGX
Negative Multiple: -101.2

EV/FCFF Forward Multiples

Forward EV/FCFF multiple is a version of the EV/FCFF ratio that uses forecasted free cash flow to firm for the EV/FCFF calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to firm forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/FCFF
N/A
2-Years Forward
EV/FCFF
N/A
3-Years Forward
EV/FCFF
N/A

See Also

Discover More